益盛药业(002566) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥159,128,536.54, a decrease of 20.59% compared to ¥200,387,679.60 in the same period last year[4] - Net profit attributable to shareholders was ¥11,861,570.02, down 43.56% from ¥21,016,379.98 year-on-year[4] - Basic and diluted earnings per share were both ¥0.0358, reflecting a decline of 43.62% from ¥0.0635 in the prior year[4] - Total operating revenue decreased to ¥159.13 million from ¥200.39 million, a decline of approximately 20.5% year-over-year[20] - Net profit fell to ¥12.04 million from ¥21.42 million, a decrease of approximately 43.7% year-over-year[21] - Operating profit decreased to ¥14.28 million from ¥26.33 million, a decline of about 45.7% year-over-year[21] - Cash flow from operating activities generated ¥22.04 million, down from ¥42.77 million, a decrease of approximately 48.6% year-over-year[22] - Basic and diluted earnings per share decreased to ¥0.0358 from ¥0.0635, a decline of about 43.5% year-over-year[21] Cash Flow and Investments - The net cash flow from operating activities decreased by 48.48%, amounting to ¥22,039,481.20 compared to ¥42,774,958.89 in the previous year[4] - Cash flow from investing activities showed a net outflow of ¥17.29 million compared to an inflow of ¥39.51 million in the previous period[22] - Cash flow from financing activities increased to ¥34.12 million from a net outflow of ¥4.36 million, indicating a significant improvement[23] - The ending cash and cash equivalents balance was ¥110.35 million, down from ¥565.65 million, a decrease of approximately 80.5% year-over-year[23] - The company reported a significant increase in cash inflow from investment activities, totaling ¥119.84 million compared to ¥50 million in the previous period[22] Assets and Liabilities - Total assets increased by 1.41% to ¥3,012,426,739.73 from ¥2,970,654,385.62 at the end of the previous year[4] - Total current assets rose to ¥2,426,571,304.74 from ¥2,375,780,311.63, indicating an increase of about 2.1%[15] - Short-term borrowings increased to ¥345,018,874.14 from ¥290,283,555.56, marking a rise of about 19%[17] - The total liabilities amounted to ¥666,955,707.71, compared to ¥637,219,990.02, showing an increase of approximately 4.9%[17] - The company's total equity rose to ¥2,345,471,032.02 from ¥2,333,434,395.60, reflecting a growth of about 0.5%[18] - The retained earnings increased to ¥936,434,288.86 from ¥924,572,718.84, indicating a growth of approximately 1.4%[18] Shareholder Information - The company had a total of 20,530 common shareholders at the end of the reporting period[10] - The largest shareholder, Zhang Yisheng, holds 39.08% of the shares, totaling 129,348,530 shares[10] Regulatory and Compliance Issues - The company is implementing a rectification plan to address issues related to shareholding disclosure, with certain shareholders no longer having shareholding proxies[12] - The company aims to resolve the proxy shareholding issue in the shortest time possible while considering the impact on the secondary market[12] - The company has received administrative penalties due to false disclosures related to shareholding, affecting multiple responsible individuals[12] Financial Expenses - Financial expenses surged by 428.31%, reaching ¥3,003,191.18, primarily due to a decrease in interest income[9] Prepayments - The company reported a significant increase in prepayments, rising by 253.92% to ¥5,585,608.87 due to increased advance payments to suppliers[8]